The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Cited by
Sorted by citations
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 528
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Baulu, E., Gardet, C., Chuvin, N., & Depil, S. (2023) · Science Advances · doi:10.1126/sciadv.adf3700 · Cited by 474
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 372
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A.-T. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 352
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Hassel, J. C., Piperno‐Neumann, S., Rutkowski, P. L., Baurain, J., Schlaak, M. S., Butler, M. O., Sullivan, R. J., Dummer, R., Kirkwood, J. M., Orloff, M. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304753 · Cited by 317
Self-citationEuropean consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Basset‐Séguin, N., Bastholt, L., Bataille, V. A., del Mármol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.018 · Cited by 309
Self-citationAdvances in the clinical management of uveal melanoma
Carvajal, R. D., Sacco, J. J., Jager, M. J., Eschelman, D. J., Bagge, R. O., Harbour, J. W., Chieng, N. D., Patel, S. P., Joshua, A. M., & Piperno-Neumann, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00714-1 · Cited by 289
Self-citationKaplon, H., Crescioli, S., Chenoweth, A. M., Visweswaraiah, J., & Reichert, J. M. (2022) · mAbs · doi:10.1080/19420862.2022.2153410 · Cited by 278
T-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 275
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00690-x · Cited by 292
Systemic Therapy for Melanoma: ASCO Guideline Update
Seth, R., Agarwala, S. S., Messersmith, H. J., Alluri, K. C., Ascierto, P. A., Atkins, M. B., Bollin, K. B., Chacon, M. R., Davis, N. B., Faries, M. B., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01136 · Cited by 251
Self-citationNew immune cell engagers for cancer immunotherapy
Fenis, A., Demaria, O., Gauthier, L., Vivier, É., & Narni-Mancinelli, É. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00982-7 · Cited by 214
Managing Metastatic Melanoma in 2022: A Clinical Review
Switzer, B., Puzanov, I., Skitzki, J. J., Hamad, L., & Ernstoff, M. S. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00686 · Cited by 214
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Goebeler, M.-E., Stuhler, G., & Bargou, R. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00905-y · Cited by 195
ALK-positive lung cancer: a moving target
Schneider, J. L., Lin, J. J., & Shaw, A. T. (2023) · Nature Cancer · doi:10.1038/s43018-023-00515-0 · Cited by 198
Bispecific antibodies: advancing precision oncology
Herrera, M., Pretelli, G., Desai, J., Garralda, E., Siu, L. L., Steiner, T. M., & Au, L. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.002 · Cited by 193
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Wei, J., Yang, Y., Wang, G., & Liu, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035276 · Cited by 195
Advances in antibody-based therapy in oncology
Zinn, S., Vazquez-Lombardi, R., Zimmermann, C., Sapra, P., Jermutus, L., & Christ, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00516-z · Cited by 187
Kirchhammer, N., Trefny, M. P., der Maur, P. A., Laubli, H. P., & Zippelius, A. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3605 · Cited by 182
The treatment of advanced melanoma: Current approaches and new challenges
Boutros, A., Croce, E., Ferrari, M., Gili, R., Massaro, G., Marconcini, R., Arecco, L., Tanda, E. T., & Spagnolo, F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104276 · Cited by 180
Emens, L. A., Romero, P. J., Anderson, A. C., Bruno, T. C., Capitini, C. M., Collyar, D. E., Gulley, J. L., Hwu, P., Posey, A. D., Silk, A. W., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009063 · Cited by 175
Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A. P., Hernandez-Aya, L. F., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02015-7 · Cited by 167
Self-citationMetastatic uveal melanoma: The final frontier
Rantala, E., Hernberg, M. M., Piperno‐Neumann, S., Grossniklaus, H. E., & Kivelä, T. T. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101041 · Cited by 169
Self-citationT cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A., & Ribas, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00809-z · Cited by 164
Molecular tumour boards — current and future considerations for precision oncology
Tsimberidou, A. M., Kahle, M., Vo, H. H., Baysal, M. A., Johnson, A. M., & Meric‐Bernstam, F. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00824-4 · Cited by 145
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Huang, H., Yao, Y., Deng, X., Huang, Z., Chen, Y., Wang, Z., Hong, H., Huang, H., & Lin, T. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5545 · Cited by 141
Merino, M., Kasamon, Y. L., Theoret, M. R., Pazdur, R., Kluetz, P. G., & Gormley, N. J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00225 · Cited by 145
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 146
Tasdogan, A., Sullivan, R. J., Katalinic, A., Lebbé, C., Whitaker, D., Puig, S., van de Poll-Franse, L. V., Massi, D., & Schadendorf, D. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00603-8 · Cited by 143
Self-citationThe landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 140
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0964 · Cited by 125
Dhillon, S. (2022) · Drugs · doi:10.1007/s40265-022-01704-4 · Cited by 116
Turning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 118
Wang, M. M., Coupland, S. E., Aittokallio, T. A., & Figueiredo, C. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02361-4 · Cited by 115
Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
Poole, A. J., Karuppiah, V., Hartt, A., Haidar, J. N. S., Moureau, S., Dobrzycki, T., Hayes, C., Rowley, C. N., Dias, J. C., Harper, S. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32811-1 · Cited by 115
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 114
Huang, Y., Li, J., Li, M., & Aparasu, R. R. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-02078-1 · Cited by 108
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Basset‐Séguin, N., Bastholt, L., Bataille, V. A., Brochez, L., del Mármol, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115153 · Cited by 107
Self-citationCarvajal, R. D., Nathan, P., Sacco, J. J., Orloff, M., Hernandez-Aya, L. F., Yang, J., Luke, J. J., Butler, M. O., Stanhope, S., Collins, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01805 · Cited by 95
Self-citationImaging of Uveal Melanoma—Current Standard and Methods in Development
Solnik, M., Paduszyńska, N., Czarnecka, A. M., Synoradzki, K. J., Yousef, Y. A., Chorągiewicz, T., Ręjdak, R., Toro, M. D., Zweifel, S. A., Dyndor, K., et al. (2022) · Cancers · doi:10.3390/cancers14133147 · Cited by 92
The next generation of immunotherapies for lung cancers
Zhao, S., Zhao, H., Yang, W., & Zhang, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01035-9 · Cited by 96
Recent advances and challenges of bispecific antibodies in solid tumors
Wu, Y., Yi, M., Zhu, S., Wang, H., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00250-1 · Cited by 93
Zhao, L., Li, S., Wei, X., Qi, X., Liu, D., Liu, L., Wen, F., Zhang, J., Wang, F., Liu, Z., et al. (2022) · Blood · doi:10.1182/blood.2022016243 · Cited by 92
Géraud, A., Hueso, T., Laparra, A., Bigé, N., Ouali, K., Cauquil, C. A., Stoclin, A., Danlos, F., Hollebecque, A., Ribrag, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114075 · Cited by 91
Design of high-specificity binders for peptide–MHC-I complexes
Liu, B., Greenwood, N. F., Bonzanini, J. E., Motmaen, A., Meyerberg, J., Dao, T., Xiang, X., Ault, R., Sharp, J., Wang, C., et al. (2025) · Science · doi:10.1126/science.adv0185 · Cited by 90
Precision cancer medicine: Concepts, current practice, and future developments
Edsjö, A., Holmquist, L., Geoerger, B., Nowak, F., Gomon, G., Alix‐Panabières, C., Staaf, J., Ploeger, C., Lassen, U., Tourneau, C. L., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13709 · Cited by 91
Persson, M. L., Douglas, A. M., Alvaro, F., Faridi, P., Larsen, M. R., Alonso, M. M., Vitanza, N. A., & Dun, M. D. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac117 · Cited by 85
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities
Baeuerle, P. A., & Wesche, H. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000869 · Cited by 78
Emerging Trends in Immunotherapy for Cancer
Mishra, A., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 79
Hong, Y., Nam, S.-M., & Moon, A. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01433-6 · Cited by 75
Bagge, R. O., Nelson, A., Shafazand, A., All‐Eriksson, C., Cahlin, C., Elander, N., Helgadóttir, H., Kiilgaard, J. F., Kinhult, S., Ljuslinder, I., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01705 · Cited by 73
T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions
Shanshal, M., Caimi, P. F., Adjei, A. A., & Ma, W. W. (2023) · Cancers · doi:10.3390/cancers15102824 · Cited by 73
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 74
Self-citationCurrent management of uveal melanoma: A review
Bai, H.-X., Bosch, J. J., & Heindl, L. M. (2023) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14214 · Cited by 70
Harbour, J. W., Corrêa, Z. M., Schefler, A. C., Mruthyunjaya, P., Materin, M. A., Aaberg, T. A., Skalet, A. H., Reichstein, D. A., Weis, E., Kim, I. K., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00447 · Cited by 69
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
van de Donk, N. W. C. J., Chari, A., & Mateos, M. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00186-8 · Cited by 65
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez‐Maffe, J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02133-6 · Cited by 64
Self-citationTebentafusp: a first-in-class treatment for metastatic uveal melanoma
Howlett, S., Carter, T. J., Shaw, H. M., & Nathan, P. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160140 · Cited by 64
Self-citationA pivotal decade for bispecific antibodies?
Surowka, M., & Klein, C. (2024) · mAbs · doi:10.1080/19420862.2024.2321635 · Cited by 64
Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions
Lamas, N. J., Martel, A., Nahon‐Estève, S., Goffinet, S., Macocco, A., Bertolotto, C., Lassalle, S., & Hofman, P. M. (2021) · Cancers · doi:10.3390/cancers14010096 · Cited by 65
Recent Advances and Challenges in Uveal Melanoma Immunotherapy
Fu, Y., Xiao, W., & Mao, Y. (2022) · Cancers · doi:10.3390/cancers14133094 · Cited by 63
Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.02.010 · Cited by 62
Jilani, S., Saco, J. D., Mugarza, E., Pujol-Morcillo, A., Chokry, J., Ng, C., Abril-Rodríguez, G., Berger-Manerio, D., Pant, A., Hu, J. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45221-2 · Cited by 60
Uveal melanoma: In the era of new treatments
Wespiser, M., Neidhardt, E., & Négrier, S. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102599 · Cited by 57
Rossi, E., Croce, M., Reggiani, F., Schinzari, G., Ambrosio, M., Gangemi, R. M. R., Tortora, G., Pfeffer, U., & Amaro, A. A. (2021) · Cancers · doi:10.3390/cancers13225684 · Cited by 56
Zager, J. S., Orloff, M. M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., Ejaz, A. M., Howard, J. H., Richtig, E., Ochsenreither, S., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15293-x · Cited by 55
Self-citationCurrent landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM
Saotome, K., Dudgeon, D., Colotti, K., Moore, M. J., Jones, J. L., Zhou, Y., Rafique, A., Yancopoulos, G. D., Murphy, A. J., Lin, J. C.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37532-7 · Cited by 56
Acral melanoma: new insights into the immune and genomic landscape
Carvalho, L. A. D. C., Aguiar, F. C., Smalley, K. S. M., & Possik, P. A. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100947 · Cited by 53
Bispecific antibodies: unleashing a new era in oncology treatment
Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 51
Chen, L. N., & Carvajal, R. D. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2124971 · Cited by 52
Self-citationUveal melanoma: Current evidence on prognosis, treatment and potential developments
Gelmi, M. C., & Jager, M. J. (2024) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2024.100060 · Cited by 49
Gp-100 as a Novel Therapeutic Target in Uveal Melanoma
Martínez-Pérez, D., Viñal, D., Solares, I., Espinosa, E., & Feliú, J. (2021) · Cancers · doi:10.3390/cancers13235968 · Cited by 49
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
Simão, D. C., Zarrabi, K. K., Mendes, J. L., da Luz, R., Garcia, J. A., Kelly, W. K., & Barata, P. C. (2023) · Cancers · doi:10.3390/cancers15051412 · Cited by 47
Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
Olivier, T., Haslam, A., Tuia, J. E., & Prasad, V. K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.38612 · Cited by 47
Piulats, J. M., Watkins, C. L., Costa-García, M., del Carpio, L. P., Piperno-Neumann, S., Rutkowski, P. L., Hassel, J. C., Espinosa, E., de la Cruz‐Merino, L., Ochsenreither, S., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.013 · Cited by 47
Self-citationImmunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49
The Warburg Effect: Is it Always an Enemy?
Papaneophytou, C. P. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2912402 · Cited by 49
Combination Therapies for the Optimisation of Bispecific T-Cell Engagers in Cancer Treatment
Zhu, W. M., & Middleton, M. R. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad013 · Cited by 46
Rohaan, M. W., Gomez-Eerland, R., van den Berg, J. H., Foppen, M. H. G., van Zon, M., Raud, B., Jedema, I., Scheij, S., de Boer, R., Bakker, N. A. M., et al. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100089 · Cited by 46
Cheng, L., Chen, L., Shi, Y., Gu, W., Ding, W., Zheng, X. W., Liu, Y., Jiang, J., & Zheng, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01956-6 · Cited by 49
Darovasertib, a novel treatment for metastatic uveal melanoma
Cao, L., Chen, S., Sun, R., Ashby, C. R., Wei, L., Huang, Z., & Chen, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1232787 · Cited by 44
Kulbay, M., Marcotte, E., Remtulla, R., Lau, T. H. A., Paez-Escamilla, M. A., Wu, K. Y., & Burnier, M. N. (2024) · Biomedicines · doi:10.3390/biomedicines12081758 · Cited by 44
Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
Leonard‐Murali, S., Bhaskarla, C., Yadav, G. S., Maurya, S. K., Galiveti, C. R., Tobin, J. A., Kann, R. J., Ashwat, E., Murphy, P. S., Chakka, A. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46906-4 · Cited by 45
Rodrigues, M. J., Ramtohul, T., Rampanou, A., Sandoval, J. L., Houy, A., Servois, V., Mailly-Giacchetti, L., Pierron, G., Vincent‐Salomon, A., Cassoux, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53145-0 · Cited by 40
Self-citationSaint‐Ghislain, M., Derrien, A., Geoffrois, L., Gastaud, L., Lesimple, T., Négrier, S., Penel, N., Kurtz, J., Corre, Y. L., Dutriaux, C., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.033 · Cited by 40
Self-citationVerschoor, N., Bos, M. K., Hoop, E. O., Martens, J. W. M., Sleijfer, S., Jager, A., & Beije, N. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114159 · Cited by 39
Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome
Leung, K., Schaefer, K., Lin, Z., Yao, Z. W., & Wells, J. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00554 · Cited by 44
Innovative strategies for T cell engagers for cancer immunotherapy
Bergamaschi, C., Gaspar, M., Ciucci, T., Sitnikova, S. I., Cayatte, C., Pica, M., & Dovedi, S. J. (2025) · mAbs · doi:10.1080/19420862.2025.2531223 · Cited by 39
Evolution and modulation of antigen-specific T cell responses in melanoma patients
Huuhtanen, J., Chen, L., Jokinen, E., Kasanen, H. H. E., Lönnberg, T., Kreutzman, A. S., Peltola, K. J., Hernberg, M., Wang, C., Yee, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33720-z · Cited by 38
Lameris, R., Ruben, J. M., Iglesias‐Guimarais, V., de Jong, M., Veth, M., van de Bovenkamp, F. S., de Weerdt, I., Kater, A. P., Zweegman, S., Horbach, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100961 · Cited by 40
Smith, K. E. R., Peng, K.-W., Pulido, J. S., Weisbrod, A. J., Strand, C. A., Allred, J. B., Newsom, A. N., Zhang, L., Packiriswamy, N., Kottke, T. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1279387 · Cited by 38
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Yamada, K., Takeuchi, M., Fukumoto, T., Suzuki, M., Kato, A., Mizuki, Y., Yamada, N., Kaneko, T., Mizuki, N., & Horita, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-55675-5 · Cited by 38
The potential and promise for clinical application of adoptive T cell therapy in cancer
Li, Y., Zheng, Y., Liu, T., Liao, C., Shen, G., & He, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05206-7 · Cited by 41
Targeting the tumour cell surface in advanced prostate cancer
Boixareu, C., Taha, T., Venkadakrishnan, V. B., Bono, J. S. D., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01014-w · Cited by 43
Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1975–2020)
Weinberger, Y., Bena, J., & Singh, A. D. (2024) · Ocular Oncology and Pathology · doi:10.1159/000543151 · Cited by 38
Challenges and solutions for therapeutic TCR ‐based agents
Malviya, M., Aretz, Z. E. H., Molvi, Z., Lee, J., Pierre, S. A., Wallisch, P., Dao, T., & Scheinberg, D. A. (2023) · Immunological Reviews · doi:10.1111/imr.13233 · Cited by 37
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
